CJC 1295 No DAC 5mg+IPA 5mg – 10mg (10 vials)

CJC-1295 No DAC 5mg + Ipamorelin 5mg – 10mg – 10 Vials

Product Overview

This combination product is listed as containing CJC-1295 No DAC and Ipamorelin, two synthetic peptides investigated for their roles in growth hormone-related signaling pathways.

CJC-1295 No DAC is associated with growth hormone-releasing hormone (GHRH) receptor activity. Ipamorelin is a selective ghrelin receptor agonist that has been studied for its interaction with pathways involved in growth hormone release.

The two ingredients have distinct biological targets. Their inclusion in one product does not establish that the combination is safe or effective for therapeutic use.

Product Details

• Product Name: CJC-1295 No DAC + Ipamorelin
• CJC-1295 No DAC: 5mg
• Ipamorelin: 5mg
• Combined Listed Amount: 10mg
• Package Quantity: 10 vials
• Product Category: Synthetic Peptide Combination
• Research Areas: GHRH and ghrelin receptor signaling
• Manufacturer: Confirm with supplier
• Formulation: Confirm with supplier
• Storage Requirements: Follow verified manufacturer documentation

Scientific Background

CJC-1295 No DAC

CJC-1295 No DAC, commonly associated with Mod GRF (1-29), is a synthetic peptide studied in relation to GHRH receptor activity and growth hormone signaling. It does not contain the Drug Affinity Complex modification associated with the DAC version.

Ipamorelin

Ipamorelin is a synthetic peptide that acts as a ghrelin receptor agonist. It has been investigated for its interaction with signaling pathways involved in growth hormone release.

Although both compounds have been studied in relation to growth hormone regulation, research findings do not establish the safety or effectiveness of this specific combination product in humans.

Product Verification

Before publishing or distributing this product, confirm:

• Whether each vial contains 5mg of each peptide
• Whether the combined 10mg amount applies to each vial
• Exact ingredient identities and formulation
• Manufacturer identity and product labeling
• Batch identification and available quality documentation
• Storage and handling requirements
• Applicable regulatory status and distribution requirements

Important Safety and Regulatory Information

CJC-1295 No DAC and Ipamorelin are investigational peptides and should not be presented as approved treatments or as proven safe and effective for human use. Their combination requires particular care when describing research findings, and no therapeutic benefits should be assumed.

This description is for product identification and general research information only. It is not medical advice, a dosing guide, or a recommendation for human administration. Verify the product’s identity and regulatory status before publication.